Immunotherapies targeting Tregs
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
50
NCT06622486
First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors
Phase: Phase 1/2
Role: Lead Sponsor
Start: Sep 27, 2024
Completion: Jan 23, 2027
Loading map...